文献速递心脏核医学放射性药物与辐射防护

XTR004(一种新型18F标记心肌灌注PET示踪剂)的I期首次人体研究:静息状态下单次注射后的生物分布、辐射剂量学、药代动力学和安全性

Phase I, first-in-human study of XTR004, a novel 18F-labeled tracer for myocardial perfusion PET: Biodistribution, radiation dosimetry, pharmacokinetics, and safety after a single injection at rest.
PubMed 文献 · J Nucl Cardiol · 2024-02-13

本研究在11名健康受试者中评估了新型18F标记心肌灌注PET示踪剂XTR004静息单次注射(239-290 MBq)后的影像特征、药代动力学和安全性。心肌摄取迅速达到4.72 %ID并在1小时内稳定,全身有效剂量为0.0165 mSv/MBq,7/11受试者出现治疗相关不良事件但无严重不良事件。结论认为XTR004安全性良好、心肌摄取快速高且稳定,具备PET心肌灌注显像的优良潜力,需进一步探索其检测心肌缺血的价值。

要点

  • 11名健康受试者静息注射XTR004 239-290 MBq,心肌摄取1小时内稳定(Δ: 7.20%,5.95%)。
  • 全身有效剂量为0.0165 mSv/MBq,累积尿排泄8.18%。
  • 治疗相关不良事件发生于7/11(63.6%)受试者,未报告严重不良事件。

核心结论

  • XTR004表现出良好的安全性、快速高且稳定的心肌摄取,以及用于PET心肌灌注显像的优良潜力。
  • 需进一步探索XTR004 PET心肌灌注显像检测心肌缺血的价值。

研究设计与样本

  • I期首次人体研究,纳入11名健康受试者(8名男性、3名女性),静脉注射XTR004 239-290 MBq。
  • 在给药当日及三次随访中监测安全性;4.7小时内进行多次全身PET扫描评估生物分布和辐射剂量学;采集7.25小时内的血液和尿液样本进行代谢校正以表征药代动力学。

主要发现

  • 10名受试者0-12分钟PET图像中,肝脏(26.81 ± 4.01)、肾脏(11.43 ± 2.49)、肺(6.75 ± 1.76)、心肌(4.72 ± 0.67)和脾脏(3.1 ± 0.84)的注射剂量百分比(%ID)最高。
  • 心肌摄取初始达4.72 %ID和7.06 g/mL,1小时内变化可忽略(Δ: 7.20%,5.95%)。
  • 代谢校正后血浆放射性峰值出现在2.5分钟(0.0013896 %ID/g),半衰期为45.2分钟。
  • 全身有效剂量为0.0165 mSv/MBq,累积尿排泄为8.18%。
  • 治疗相关不良事件发生于7/11名受试者(63.6%),未报告严重不良事件。

临床怎么用

  • 作者认为XTR004具有良好的安全性、快速高且稳定的心肌摄取以及用于PET心肌灌注显像的优良潜力。
  • 作者指出需进一步探索XTR004 PET心肌灌注显像检测心肌缺血的价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study assessed the imaging characteristics, pharmacokinetics and safety of XTR004, a novel 18F-labeled Positron Emission Tomography (PET) myocardial perfusion imaging tracer, after a single injection at rest in humans. METHODS: Eleven healthy subjects (eight men and three women) received intravenous XTR004 (239-290 megabecquerel [MBq]). Safety profiles were monitored on the dosing day and three follow-up visits. Multiple whole-body PET scans were conducted over 4.7 h to evaluate biodistribution and radiation dosimetry. Blood and urine samples collected for 7.25 h were metabolically corrected to characterize pharmacokinetics. RESULTS: In the first 0-12 min PET images of ten subjects, liver (26.81 ± 4.01), kidney (11.43 ± 2.49), lung (6.75 ± 1.76), myocardium (4.72 ± 0.67) and spleen (3.1 ± 0.84) exhibited the highest percentage of the injected dose (%ID). Myocardial uptake of XTR004 in the myocardium initially reached 4.72 %ID and 7.06 g/mL, and negligibly changed within an hour (Δ: 7.20%, 5.95%). The metabolically corrected plasma peaked at 2.5 min (0.0013896 %ID/g) and halved at 45.2 min. Whole-body effective dose was 0.0165 millisievert (mSv)/MBq. Cumulative urine excretion was 8.18%. Treatment-related adverse events occurred in seven out of eleven subjects (63.6%), but no severe adverse event was reported. CONCLUSIONS: XTR004 demonstrated a favorable safety profile, rapid, high, and stable myocardial uptake and excellent potential for PET myocardial perfusion imaging (MPI). Further exploration of XTR004 PET MPI for detecting myocardial ischemia is warranted.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Ren C, Pan Q, Fu C, et al. Phase I, first-in-human study of XTR004, a novel 18F-labeled tracer for myocardial perfusion PET: Biodistribution, radiation dosimetry, pharmacokinetics, and safety after a single injection at rest. J Nucl Cardiol. 2024. PMID: 38360262. doi:10.1016/j.nuclcard.2024.101823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。